@inbook{4122b663a35f443f86daa27ca922c5c9,
title = "Skin reactions to immune checkpoint inhibitors",
abstract = "The novelty of immune checkpoint inhibitors has only recently led to the characterization of cutaneous adverse events (AEs). This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat. In the following chapter, we will review the categories of these drugs, common cutaneous effects, their grading, and management options.",
keywords = "Anti-CTLA4, Anti-PD1, Dermatitis, Dermatitis, Immune checkpoint inhibitors, Immunotherapy, Ipilimumab, Nivolumab, Pruritus, Rash",
author = "Patel, {Anisha B.} and Omar Pacha",
note = "Publisher Copyright: {\textcopyright} Springer International Publishing AG 2017.",
year = "2017",
doi = "10.1007/978-3-319-53156-4_9",
language = "English (US)",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "175--184",
booktitle = "Advances in Experimental Medicine and Biology",
}